Award
National Cancer Institute 5R01CA258688-05
Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer
Recipient
Not specified
Award Amount
$407,175.00
Ceiling
$407,175.00
Awarded
March 13, 2025
Identifier
5R01CA258688-05
The project aims to develop effective immunotherapy for triple negative breast cancer by inhibiting key pathways involved in STING degradation, utilizing novel delivery systems, and conducting comprehensive preclinical studies.
Description
This NIH grant supports research on enhancing the efficacy of STING agonists for triple negative breast cancer by preventing drug degradation and improving delivery methods, including embedding into PEGylated breast biopsy markers. The project involves in vivo pharmacokinetics, molecular targeting, and innovative drug delivery strategies to improve therapeutic outcomes.